When IL-2 and Tregs are concomitantly administered to T1D recipients, IL-2 induces the proliferation not only of Tregs, but also of potentially cytotoxic cells, highlighting the need for Treg specific IL-2 (228). This evidence concerns the gene IL2 and type 1 diabetes mellitus.